The Japan Clinical Cancer Research Organization (JACCRO) has reported positive effects of re-administration of anti-EGFR antibody drugs (Cmab: JACCRO-CC08 and Pmab: JACCRO-CC09) [6,10]; however, these reports only referred to side effects at the time of re-administration. Here, EGFR is linked to cancer.